Michael Rausch, MD
Family Medicine · Augusta, KSNPI 1528173705
Payments from drug & device makers
What this record shows
33 manufacturers reported payments, led by Pfizer at 27.0% of the total. Reporting peaked in 2019 at $3,211 and has fallen 80.5% since, to $627 in 2025. Among family medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $51.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Alnylam Pharmaceuticals Inc.$2K
- Seqirus USA Inc$1K
- AstraZeneca$972
- Bayer$331
- Lilly USA, LLC$247
- plus $1K from 27 others
Across 2,433 payments — averaging $3361.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.1M
- Pfizer$930K
- GSK$772K
- Emergent Biosolutions Inc.$731K
- Valneva Austria GmbH$670K
- Seqirus USA Inc$285K
- plus $1.7M from 17 others
What the payments were for
- Travel & lodging$3,46845%
- Food & beverage$4,27355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $2,092 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,623 |
| Seqirus USA Inc | 4 | $1,162 |
| AstraZeneca | 29 | $972 |
| Bayer | 14 | $331 |
| Lilly USA, LLC | 17 | $247 |
| AbbVie | 11 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $139 |
| Novo Nordisk | 1 | $125 |
| GSK | 6 | $122 |
| Amgen | 2 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $73 |
| Cranial Technologies, Inc | 3 | $55 |
| Novartis | 3 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Exact Sciences | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Johnson & Johnson | 2 | $22 |
| Eisai Inc. | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| CTL Medical Corporation | 2 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Merck | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,741 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 78 | $55,916 |
| MounjaroTirzepatide | 40 | $42,430 |
| EliquisApixaban | 64 | $40,772 |
| TrulicityDulaglutide | 35 | $38,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $36,255 |
| JardianceEmpagliflozin | 37 | $25,073 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $21,282 |
| JanuviaSitagliptin Phosphate | 39 | $17,120 |
| MyrbetriqMirabegron | 24 | $16,080 |
| XareltoRivaroxaban | 17 | $14,127 |
| LinzessLinaclotide | 25 | $13,861 |
| OzempicSemaglutide | 11 | $10,312 |
| Diazepam | 32 | $10,247 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 30 | $8,926 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $8,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $247 | $80,68775 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $972 | $77,198111 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Incruse Ellipta | $122 | $57,948121 claims |
| PfizerEliquis, Abrysvo | $2,092 | $48,88590 claims |
| MerckJanuvia | $12 | $17,12039 claims |
| Johnson & JohnsonXarelto | $22 | $14,12717 claims |
| AbbVieLinzess | $244 | $13,86125 claims |
| Novo NordiskOzempic | $125 | $10,31211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Augusta
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.